R9Q Stoklara Genel Bakış Recce Pharmaceuticals Ltd, Avustralya, Birleşik Krallık ve Amerika Birleşik Devletleri'nde sentetik anti-enfektifler keşfetmekte, geliştirmekte ve ticarileştirmektedir. Daha fazla detay
Risk Analizi + 1 daha fazla risk
Tüm Risk Kontrollerini Gör {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Recce Pharmaceuticals Ltd Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Recce Pharmaceuticals Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı AU$0.24 52 Haftanın En Yüksek Seviyesi AU$0.38 52 Haftanın En Düşük Seviyesi AU$0.23 Beta 1.04 1 Aylık Değişim -7.75% 3 Aylık Değişim -10.53% 1 Yıllık Değişim -17.36% 3 Yıllık Değişim -64.21% 5 Yıllık Değişim n/a Halka arzdan bu yana değişim -26.52%
Son Haberler & Güncellemeler
Recce Pharmaceuticals Ltd Doses All Patients in Phase II Trial of Recce®? 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections Jan 22
Recce Pharmaceuticals Ltd Receives Approval from Indonesia's Drug and Food Authority for Registrational Phase 3 Trial of Recce®? 327 Topical Gel in Diabetic Foot Infections Dec 11
Recce Pharmaceuticals Ltd Receives Ethics Approval in Indonesia to Commence Registrational Phase 3 Trial of Recce®?327 Topical Gel in Diabetic Foot Infections Nov 12
Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections Nov 06
Recce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections Oct 10
Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 06, 2024 Sep 16 Daha fazla güncelleme görün
Recce Pharmaceuticals Ltd Doses All Patients in Phase II Trial of Recce®? 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections Jan 22
Recce Pharmaceuticals Ltd Receives Approval from Indonesia's Drug and Food Authority for Registrational Phase 3 Trial of Recce®? 327 Topical Gel in Diabetic Foot Infections Dec 11
Recce Pharmaceuticals Ltd Receives Ethics Approval in Indonesia to Commence Registrational Phase 3 Trial of Recce®?327 Topical Gel in Diabetic Foot Infections Nov 12
Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections Nov 06
Recce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections Oct 10
Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 06, 2024 Sep 16
New major risk - Revenue and earnings growth Jul 16
Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter Baumannii Jul 10 Recce Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 2 million.
Recce Pharmaceuticals Reports Positive Data from Phase I/Ii Urinary Tract Infection (Uti) / Urosepsis Rapid Infusion Trial of Recce® 327 Jul 03
Recce Pharmaceuticals Ltd. Receives Ethics Approval to Broaden RECCE 327 Gel Trials Across All Topical Bacterial Skin Infections Jun 25
Recce Pharmaceuticals Announces Addition of RECCE® 327 to the World Health Organization’S List of Antibacterial Products in Clinical Development Jun 20
Recce Pharmaceuticals Ltd Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial May 18
Recce Pharmaceuticals Reports Positive Preclinical Data of Recce® 327 in Lung Infection Pilot Study May 15
Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration May 09
New major risk - Revenue and earnings growth May 08
Recce Pharmaceuticals Ltd. Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis Apr 30
Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice Apr 17
Recce Pharmaceuticals Ltd Receives New Patent in Israel for Recce Anti-Infectives Apr 05
New major risk - Revenue and earnings growth Mar 27
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of Recce® 327 for Urinary Tract Infections and Urosepsis Mar 20
Recce Pharmaceuticals Ltd Doses Next Cohort in Phase I/II Trial of RECCE 327 for Urinary Tract Infections and Urosepsis Mar 14
New major risk - Share price stability Mar 13
Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE 327 for the Treatment of Diabetic Foot Infections Jan 23
Recce Pharmaceuticals Receives Ausindustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program Dec 20
Recce Pharmaceuticals Ltd Reports Positive Preclinical Data of RECCE 327 Against Gonorrhoeae Dec 19
Recce Pharmaceuticals Limited Announces Canadian Patent Granted for Recce® Anti-Infectives Nov 23
Recce Pharmaceuticals Ltd Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis Nov 10
Recce Pharmaceuticals Ltd Announces Safety Committee Approves Faster Infusion Rate in Phase I/Ii Trial of Recce® 327 for Urinary Tract Infections and Urosepsis Oct 26 Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million. Oct 06
Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million. Oct 05
Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.715261 million. Sep 29
Recce Pharmaceuticals Completes Dosing in Phase I/II Clinical Trial of Recce® 327 for Urinary Tract Infections Sep 27
Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 8 million. Sep 20 Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 8 million.
Recce Pharmaceuticals Ltd Provides Additional Positive Update on Patients Treated Under "Special Access Scheme" Sep 02
New minor risk - Financial data availability Aug 30
Recce Pharmaceuticals Ltd Announces Safety Committee Approves Next Dose of Recce®? 327 At 3,000Mg in Phase I/Iiuti/Urosepsis Rapid Infusion Clinical Trial Aug 30
Recce Pharmaceuticals Ltd Doses Patients in Phase I/II Clinical Trial of Recce 327 for Diabetic Foot Infections Aug 25
Recce Pharmaceuticals Ltd. Completes Stage 1 Data Analysis of Phase I/II Clinical Trial for the Treatment of Burn Wound Infections Aug 24
Recce Pharmaceuticals Ltd Provides Positive Update on Patients Treated with RECCE®? 327 Under "Special Access Scheme" Aug 11
New major risk - Share price stability Aug 09
Recce Pharmaceuticals Completes First Cohort Dosing of Phase l/ll UTI Rapid Infusion Clinical Trial at Scientia Clinical Research Aug 02
Recce Pharmaceuticals Achieves Positive Phase I Clinical Trial Data of RECCE(R) 327 as an Intravenous Infusion Formulation Jul 23
Recce Pharmaceuticals Limited Announces First Cohort Dosed in Recce®? 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial Jul 12
CEO, MD & Executive Director recently bought €190k worth of stock Jun 29
Recce Pharmaceuticals to Be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives Jan 12
Recce Pharmaceuticals Limited Announces Australian Patent Office Issued Notification of Intent to Grant Recce's Patent Family 3 Jan 10
Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE(R) 327 in Patients with Diabetic Foot Infections Dec 13
Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase I/II Diabetic Foot Ulcer Study Dec 09
Less than half of directors are independent Nov 17 Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update Oct 19
Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update Oct 18
Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs Sep 27
Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 14, 2022 Sep 21
Recce Pharmaceuticals Appoints Alistair McKeough to Its Board of Directors and Maggie Niewidok as Company Secretary Sep 08
Recce Announces Management Changes Sep 01
Recce Pharmaceuticals Ltd Reports Positive Safety Data from Seventh Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327 Aug 22
Recce Pharmaceuticals Ltd announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE 327 and Initiates Sixth Cohort At 4,000Mg May 20
Less than half of directors are independent Apr 27
Recce Pharmaceuticals Ltd Announces Anti-Viral Patent Granted in Hong Kong Apr 12 Recce Pharmaceuticals Ltd Announces Safety Committee Clears Next Dose in Phase I Study of Recce® 327 Mar 10
Recce Pharmaceuticals Ltd Announces Positive Safety Data from Second Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327 Jan 20
Recce Pharmaceuticals Ltd Announces Patients to be Dosed in a Phase I Intravenous Clinical Trial of RECCE® 327 Dec 16
Anti-Viral Patent Grants in USA for Recce Pharmaceuticals Ltd's RECCE Anti-Infectives Jul 24
Chinese Patent Office Grants Anti-Viral Patent to Recce Pharmaceuticals Ltd Jul 20
Board Member recently sold €113k worth of stock Jun 23
Recce Pharmaceuticals Ltd. Provides Recce Clinical Pipeline Update Jun 08
Recce Pharmaceuticals Ltd Announces Positive Results of Lead Compound RECCE® 327 May 29
Recce Pharmaceuticals Ltd Announces Further Results for its Synthetic Anti-Infective R327 May 20
Recce Pharmaceuticals Ltd Announces Positive Data on RECCE 327 Against All Six ESKAPE Pathogens May 05
Recce Pharmaceuticals Ltd Announces Lead Compound Recce 327 Added to the Pew Charitable Trusts' Annual List of Non-Traditional Products Mar 15
Recce Pharmaceuticals Ltd Formalizes Fiona Stanley Hospital Phase I/Ii Clinical Trial Agreement Feb 17
Recce Pharmaceuticals Ltd Announces Encouraging Results from Anti-viral Screening Program at The Doherty Institute Evaluating RECCE® 327 Against SARS-CoV-2 Feb 14
Recce Pharmaceuticals Ltd Announces Positive Intranasal Animal Data against SARS-CoV-2 in International Study Dec 25
Recce Pharmaceuticals Ltd Announces Encouraging Preliminary Results from Antiviral Screening Program At the Doherty Institute Evaluating RECCE® 327 Against SARS-CoV-2 Nov 12
Recce Pharmaceuticals Ltd Receives Human Research Ethics Committee Approval to Start a Phase I/Ii Clinical Trial of its Broad-Spectrum Antibiotic Recce® 327 on Patients with Infected Burn Wounds Oct 17
New 90-day low: €0.63 Oct 16 Recce Pharmaceuticals Ltd announced that it has received AUD 27.95 million in funding
Recce Pharmaceuticals Ltd announced that it expects to receive AUD 27.95 million in funding Sep 24
New 90-day high - €0.91 Sep 01
Recce Pharmaceuticals Ltd Appoints James Graham as CEO Aug 29 Hissedar Getirileri R9Q DE Pharmaceuticals DE Pazar 7D 0% -3.5% 2.3% 1Y -17.4% -14.6% 16.7%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: R9Q geçen yıl % -14.6 oranında getiri sağlayan German Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: R9Q geçen yıl % 16.7 oranında getiri sağlayan German Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is R9Q's price volatile compared to industry and market? R9Q volatility R9Q Average Weekly Movement 7.5% Pharmaceuticals Industry Average Movement 5.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
İstikrarlı Hisse Senedi Fiyatı: R9Q hisse senedi fiyatı, son 3 ayda German piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: R9Q 'nin haftalık oynaklığı ( 8% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.
Şirket Hakkında Recce Pharmaceuticals Ltd, Avustralya, Birleşik Krallık ve Amerika Birleşik Devletleri'nde sentetik anti-enfektifler keşfetmekte, geliştirmekte ve ticarileştirmektedir. Şirketin öncü adayı, E. coli ve S. aureus bakterilerinden kaynaklanan kan enfeksiyonları ve sepsis tedavisi için RECCE 327 (R327)'dir. Şirket ayrıca viral enfeksiyonlar için sentetik bir anti-enfektif olan RECCE 529'u ve oral kullanım için formüle edilmiş sentetik bir polimer antibiyotik olan RECCE 435'i geliştirmektedir.
Daha fazla göster Recce Pharmaceuticals Ltd Temel Bilgiler Özeti Recce Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? R9Q temel i̇stati̇sti̇kler Piyasa değeri €61.27m Kazançlar(TTM ) -€10.73m Gelir(TTM ) €3.05m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) R9Q gelir tablosu (TTM ) Gelir AU$5.03m Gelir Maliyeti AU$7.22m Brüt Kâr -AU$2.19m Diğer Giderler AU$15.47m Kazançlar -AU$17.66m
Son Raporlanan Kazançlar
Jun 30, 2024
Hisse başına kazanç (EPS) -0.076 Brüt Marj -43.52% Net Kâr Marjı -351.24% Borç/Özkaynak Oranı -101.7%
R9Q uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/02/11 07:14 Gün Sonu Hisse Fiyatı 2025/02/11 00:00 Kazançlar 2024/06/30 Yıllık Kazançlar 2024/06/30
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin .
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github 'da mevcuttur.
Analist Kaynakları Recce Pharmaceuticals Ltd 2 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Pooya Hemami Edison Investment Research Chris Kallos MST Financial Services Pty Limited
